by EpicentRx | Feb 9, 2023 | Conferences
November 2022, San Diego, California Oral Presentation: The NLRP3 inhibitor RRx-001 crosses the blood brain barrier and alleviates neuroinflammation in experimental models of Parkinson’s disease
by EpicentRx | Feb 6, 2023 | Blog
For EpicentRx, 2023 has already been transforming—as in transforming growth factor beta (TGF-ß), which is overexpressed in most tumors. TGF-ß is a cytokine, a small protein that cells use to communicate with each other, normally released in wound areas following...
by EpicentRx | Jan 31, 2023 | Blog
“It’s like Avastin on steroids!” This direct quote came courtesy of an executive at a major pharmaceutical company after he reviewed the mechanism of action of RRx-001 and learned about the results of a Phase 2 randomized trial called ROCKET of RRx-001 vs. regorafenib...
